ライフサイエンスコーパス: healthy control

1 t-episode GAD, MDD, respectively, and n = 35 healthy controls).

2 o recover towards the diversity level of the healthy control.

3 ehyde production to two-folds as compared to healthy control.

4 ent forms of isolated focal dystonia and 220 healthy controls.

5 R, 0.89; CI, 0.80-0.99; P = .03) compared to healthy controls.

6 e clinical stratification of ALS compared to healthy controls.

7 membrane potential compared with those from healthy controls.

8 a two-sample class comparison: patients and healthy controls.

9 owing acute appendicitis did not differ from healthy controls.

10 s with GBA and LRRK2 mutations compared with healthy controls.

11 e phase in PB of aSAH patients compared with healthy controls.

12 et moderate-to-severe AD (<=6 months) and 17 healthy controls.

13 correlation was present in both patients and healthy controls.

14 have enhanced habit formation compared with healthy controls.

15 ong with 61 age- and sex-matched (by cohort) healthy controls.

16 astocytosis compared with D816V- patients or healthy controls.

17 ells in AD human skin compared with those in healthy controls.

18 nonpsychotic first-degree relatives and 202 healthy controls.

19 on the mean distribution of tract lengths in healthy controls.

20 erbation but also as a reduction relative to healthy controls.

21 s were confirmed in an independent cohort of healthy controls.

22 dissected SNpc neurons from each tier from 7 healthy controls.

23 were compared with other IBS-D patients, and healthy controls.

24 l disorders UC, CD and CRC, in comparison to healthy controls.

25 in serum from allergic patients compared to healthy controls.

26 was not observed in the oesophageal cells of healthy controls.

27 infants with CHD to 192 age- and sex-matched healthy controls.

28 T cells from 53 patients with ME/CFS and 45 healthy controls.

29 21 adults with systemic mastocytosis and 18 healthy controls.

30 BD did not show significant differences from healthy controls.

31 age (SGA) or pre-eclampsia were matched with healthy controls.

32 ohol misusers with no liver disease, and 899 healthy controls.

33 e pulmonary disease (COPD), when compared to healthy controls.

34 was noted between participants with MAS and healthy controls.

35 with FMD and 38 age-matched and sex-matched healthy controls.

36 ithout and 50 with comorbidities; and (2) 80 healthy controls.

37 ains were derived from diarrhoea patients or healthy controls.

38 rontal and frontocentral electrodes than the healthy controls.

39 (> 15%), compared with Tregs from spleen and healthy controls.

40 for HCV, 12 HIV-monoinfected persons, and 9 healthy controls.

41 h associated disorders (WAD), recovered, and healthy controls.

42 els of FUS K510 acetylation as compared with healthy controls.

43 th chronic arthritis, and in RA patients and healthy controls.

44 f p40 in serum of MS patients as compared to healthy controls.

45 lation level of PSA between PCa patients and healthy controls.

46 NC iPSC SMCs from four MFS patients and two healthy controls.

47 s and lymphangiogenesis for AR compared with healthy controls.

48 MAS; no uptake was observed in the bones of healthy controls.

49 treated with topical rhNGF, and age-matched healthy controls.

50 t of 35) of secondary MN cases, and in 0% of healthy controls.

51 nsion (IPAH) patients compared to those from healthy controls.

52 one KP metabolite between adults with BD and healthy controls.

53 ith better nutritional status, compared with healthy controls.

54 BDNF level in the classification of CAD from healthy controls.

55 o quinolinic acid (SMD = -0.37) ratios, than healthy controls.

56 e accuracy ~ 0.65) between mTBI subjects and healthy controls.

57 of total IgE was compared to the response in healthy controls.

58 ents without such behaviours, and 31 elderly healthy controls.

59 ed in ALI cultures from patients compared to healthy controls.

60 with their counterparts receiving feces from healthy controls.

61 ing skin contralateral sites as intra-animal healthy controls.

62 features of these family members compared to healthy controls.

63 chizophrenia/schizoaffective disorder and 73 healthy controls.

64 s (mean follow-up time: patients 3.41 years, healthy controls 1.97 years), we measured "brain-predict

65 ured in part of ACS patients (139/19.9%) and healthy controls (129/11.2%) randomly.

66 e mean [SD] = 14.9 +/- 1.5, 56 girls) and 47 healthy controls [14.3 +/- 1.4, 26 girls]) participated

67 ecruited (according to NIA-AA guidelines, 14 healthy controls, 14 mild Alzheimer's disease, 14 amyloi

68 young healthy volunteers, 13 age-comparable healthy controls, 18 patients with mild NMDCCC and 15 pa

69 olongation of the QTc >2 SD above historical healthy controls (2 markedly and 3 marginally) but ECGs

70 uency in the periodontitis group relative to healthy controls (21.5% versus 14.4%; odds ratio [OR] =

71 For each group of donors (32 healthy controls, 43 allergic rhinitis patients and 192

72 ents (1514 eyes) with dry eye disease and 29 healthy controls (58 eyes).

73 rain scans and 6 for whole-body scans) and 9 healthy controls (7 for brain scans and 6 for whole-body

74 We recruited 12 healthy controls, 9 IST, 30 VVS, and 30 POTS patients (1

75 aphasia (age, 67.0 +/- 7.4 y; 4 women) and 8 healthy controls (age, 69.6 +/- 7.0 y; 4 women) were sca

76 44 healthy controls (age: 33.8 (10.5), 73% female) and 84 p

77 8 with mild/moderate asthma, 16 age-matched healthy controls) aged 6 to 17 years old were imaged wit

78 nts with UC, CD and CRC patients compared to healthy controls (all p < 0.0001).

79 on-weighted MRI data were analysed from 1069 healthy controls and 1249 patients: temporal lobe epilep

80 215 patients with MK, 60 healthy controls and 35 patients with rheumatoid arthrit

81 Data obtained from healthy controls and 5 patients with intermediate AMD, b

82 s1007888 and rs2096525) was analyzed in 1153 healthy controls and 699 ACS cases in Chinese Han popula

83 Most participants including healthy controls and ACS patients carried rs755622 GG (6

84 ined in ILC2 sorted from peripheral blood of healthy controls and asthma patients or cultured with or

85 in both plasma and saliva in comparison with healthy controls and CHD.

86 obtained brain MRIs and cognitive testing in healthy controls and children with SCD.

87 rsfMRI data were acquired from healthy controls and from patients with remitted major d

88 psing-remitting (RR) MS patients compared to healthy controls and identified differentially methylate

89 Fifty subjects (28 females) including healthy controls and individuals with major depression,

90 ccurately discriminate patients with RA from healthy controls and may have practical value for RA dia

91 and neutrophil activation in comparison with healthy controls and non-COVID-19 pneumonia.

92 es in the protein decoration of sEVs between healthy controls and patients with CAP or AECOPD.

93 this technology to study differences between healthy controls and patients with celiac disease (CD).

94 ous alpha-syn from red blood cells lysate of healthy controls and PD patients.

95 able to discriminate COVID-19 patients from healthy controls and to predict mild and severe disease.

96 that differentiate Parkinson's disease from healthy controls and validated these results in an indep

97 with structural MRI diffusion imaging in our healthy controls and with blood oxygenation level-depend

98 g patients with MS and patients with CIS and healthy controls, and between disease subtypes.

99 P1 genomic segment in 2032 SLE patients, and healthy controls, and discover a low-frequency functiona

100 in CLTs in patients was much larger than in healthy controls, and in both patient groups, a proporti

101 inflammation and tissue damage compared with healthy controls, and metabolic changes associate with s

102 ailfold capillaries of patients with SSc and healthy controls are imaged and compared with each other

103 substances in all patient groups but not in healthy controls, arguing for sensitization of cutaneous

104 differentiated arthritis (UA) as compared to healthy controls as novel potential biomarkers for thera

105 datasets acquired in 17 SCI patients and 21 healthy controls at baseline (1-month post injury for pa

106 of 0.71 and discriminated ECC-converted from healthy controls at the visit immediately preceding ECC

107 of patients with LVH is greater than that of healthy controls at this early stage, further studies ar

108 Compared with healthy controls, at a global level, the structural cova

109 lanoma than unrelated cases or melanoma-free healthy controls (Bonferroni-corrected t-test P = 1.5 x

110 integrity in multiple sclerosis relative to healthy controls (both P < 0.05).

111 Compared with healthy controls, both LRRK2 and GBA non-manifesting car

112 appeared and mutant ultrastructure resembled healthy control cells.

113 While healthy control children showed increased connectivity i

114 r experiment, chronic back pain patients and healthy controls completed an appetitive Pavlovian-instr

115 patients (14 male), 21 ES (13 male), and 21 healthy controls completed the study.

116 tional connectivity matrices with an average healthy control connectivity matrix.

117 ssays using sera collected from pre-pandemic healthy controls, COVID-19 patients at different time po

118 ns of stroke patients diverged from those of healthy controls depending on the severity of the initia

119 during maternal hyperoxia changed with GA in healthy control fetuses and fetuses with SV or AO CHD (D

120 nts (100 COVID-19 confirmed patients and 100 healthy controls) from institutions from Canada, Europe

121 nto groups: (H) systemically and periodontal healthy (control group); (P) with periodontitis, but sys

122 sease were studied along with a systemically healthy control group (HC, n = 57, F:M = 40:17).

123 ts with Fabry disease and 37.4 (53%) for the healthy control group.

124 the AD or MCI groups and those in the FCD or healthy control groups with a sensitivity of 86.7%.

125 abnormal protein signals comparing with the healthy control groups.

126 neous populations of developing cINs from 15 healthy control (HC) iPSC lines and 15 SCZ iPSC lines.

127 with OCD (12.8 +/- 2.9 years) and 23 matched healthy control (HC) participants (11.0 +/- 3.3 years) b

128 nts with DM2 without DPN (DPN negative), and healthy control (HC) participants enrolled between Augus

129 tudy participants suspected of having AM and healthy control (HC) participants were prospectively enr

130 Patients with BD and healthy control (HC) subjects underwent structural magne

131 in the individuals with CP compared with the healthy controls (HC = 286.53 +/- 30.51, 95% CI [226.74,

132 ty-eight medicine-naive MDD patients plus 33 healthy controls (HC) matched on gender, ages, and level

133 nosed after the age of 55 (LOD group) and 30 healthy controls (HC) underwent a detailed clinical asse

134 s end, 37 spider phobic patients (PP) and 32 healthy controls (HC) underwent a symptom provocation pa

135 measure the separability of SCZ and SIB from healthy controls (HC) using attentional control-dependen

136 study brain gyrification differences between healthy controls (HC), mild cognitive impairment (MCI) p

137 deep brain stimulation (DBS; ET(DBS) ) to 19 healthy controls (HC).

138 SM-5 cannabis use disorder (CUD) and matched healthy controls (HC).

139 (MDD) as compared with age- and sex-matched healthy controls (HC).

140 tion age in 331 individuals with AUD and 201 healthy controls (HC).

141 ive tendency) varied between GD patients and healthy controls (HC).

142 nificant differences between PD patients and healthy controls (HC).

143 ributes to discrimination among BD, MDD, and healthy controls (HC).

144 can differentiate psychiatric patients from healthy controls (HC).

145 erters, NCON) and we compared to age-matched healthy controls (HC).

146 49 subjects between the ages of 8 and 18 (25 healthy controls (HC); 24 BD) and quantified.

147 reezers, 22 non-freezers, and 21 age-matched healthy controls (HC)] performed a 'GO'-commanded step i

148 otic-naive and 17 antipsychotic-treated) and healthy controls (HC, N = 29).

149 chotic Bipolar disorder, n = 61) and matched healthy controls (HC, n = 60) were assessed for 15 perip

150 examined two other groups: non-psychiatric ("healthy") controls (HC) and individuals with Alzheimer's

151 alcoholic hepatitis (SAH) was compared with healthy controls (HCs) and heavy drinking controls (HDCs

152 pluripotent stem cells (iPSCs) derived from healthy controls (HCs) and individuals with SCZ and co-c

153 icrobiome in patients with PSC compared with healthy controls (HCs) and patients with inflammatory bo

154 s analyzed in 28 individuals with MDD and 22 healthy controls (HCs) at baseline, post-placebo, and po

155 with a clinical diagnosis of probable AD and healthy controls (HCs) underwent dynamic (18)F-PI-2620 P

156 teen studies describing 529 patients and 586 healthy controls (HCs) were included.

157 th multiple sclerosis (MS; n = 418 eyes), 59 healthy controls (HCs; n = 117 eyes), and 267 non-MS dis

158 is lower in ADHD patients when compared with healthy controls, however, the difference was not statis

159 ion was examined in subjects with asthma and healthy controls in bronchial epithelium from biopsies (

160 rmed PTB cases, non-TB disease controls, and healthy controls, in three cohorts (screening, selection

161 CD4(+) T cells compared to PBC patients and healthy controls, indicating increased Th17 differentiat

162 who later developed UC (post-UC) and matched healthy control individuals (HCs).

163 gher in steady-state SCA individuals than in healthy control individuals and that these cells present

164 lso sequenced DNA from blood samples from 40 healthy control individuals.

165 r double-blind crossover study that included healthy controls investigated whether eszopiclone could

166 r chondrogenic capacity when compared with a healthy control iPSC-line.

167 lent in the hemiplegic knees compared to the healthy control knees (p < 0.05).

168 fer at modelling manual segmentations in the healthy control leave-one-out analyses in two of the thr

169 Relative to healthy controls, leukocytes from patients with FMF harb

170 hibitors, a full reversal of mtDNA damage to healthy control levels was observed and correlated with

171 CKD patient's stage 3b-5 (NDD-CKD) and n=16 healthy controls matched for age, gender and physical ac

172 d clinically isolated syndrome (CIS) and 150 healthy controls (mean follow-up time: patients 3.41 yea

173 upregulated circulating YKL-40 compared with healthy controls (median 109 versus 34 ng/mL, P<0.001),

174 Compared to healthy controls, mice and glioma patients demonstrated

175 hrenia (SCZ; n = 25 each), alongside matched healthy controls (n = 100).

176 This sample included healthy controls (n = 159) and the largest cross-section

177 y preceding study entry were calculated, and healthy controls (n = 19) underwent MRI and (18)F-DPA-71

178 data were compared with the blood samples of healthy controls (n = 24) and patients with compensated

179 s in established schizophrenia (n = 307) and healthy controls (n = 364) were analysed across three si

180 d/or rMal d 3 >= 0.10 kU(A) /L (n = 182) and healthy controls (n = 37) were included.

181 les, Italian subjects with ASD (n = 398) and healthy controls (n = 379) were genotyped by PCR analysi

182 EBV genomes from both eBL cases (n = 58) and healthy controls (n = 40) residing in the same geographi

183 ds extracted from osteoarthritic (n = 5) and healthy controls (n = 5) underwent microCT imaging 39 mu

184 Major Depressive Disorder (MDD) (n = 64) to healthy controls (n = 64) using a comprehensive battery

185 56), and healthy Controls (n.

186 ples collected from human volunteers (n = 6, healthy controls; n = 14, peanut-allergic patients) at v

187 -allergic (GPA) group (n = 28) and nonatopic healthy controls (NAC, n = 13) by mathematical algorithm

188 these measures across 4 illness categories: healthy control, nonfebrile DENV, other febrile illness

189 arker proteins and compared the results with healthy controls of the same, or very similar, gestation

190 biopsies in subjects with asthma compared to healthy controls (P = .039).

191 compared to those with minimal fibrosis and healthy controls (p = 0.003).

192 with transposition of the great arteries and healthy controls (P<0.05).

193 sults Eighty participants were evaluated: 20 healthy control participants (mean age +/- standard devi

194 ars; age range, 5-58 years; five men) and 10 healthy control participants (mean age, 25 years; age ra

195 4 years +/- 15; 45 women) and 28 age-matched healthy control participants (mean age, 44 years +/- 13;

196 ight in their current depressive episode and healthy control participants (N = 42).

197 participants with NMOSDs and in age-matched healthy control participants acquired between February 2

198 , patients with other early arthritides, and healthy control participants all underwent MRI of unilat

199 2019, participants with liver cirrhosis and healthy control participants underwent hepatic and cardi

200 2018 to June 2019, participants with CF and healthy control participants underwent PFTs and function

201 ndent cohorts of probable AD and cognitively healthy control participants, and a cohort of mild cogni

202 he AD Neuroimaging Initiative were included (healthy control participants, participants with mild cog

203 sion, anxiety, and substance use) to matched healthy control participants.

204 r in patients with Alzheimer disease than in healthy control participants.

205 of 193 (98%; 95% CI: 96%, 99%) compared with healthy control participants.

206 son disease, advanced Parkinson disease, and healthy control participants.

207 red between individuals with prediabetes and healthy control participants.

208 or chronic scratching, as well as 40 matched healthy controls participated in this study.

209 Healthy control patients (n = 25) were also recruited as

210 pared with the literature data obtained from healthy control patients scanned using MOLLI, 99.3% of p

211 Results: Compared with the WM of healthy controls, patients with MS had a significantly h

212 man participants with SCA6 (13 woman) and 18 healthy controls performed fast goal-directed ankle dors

213 +/R-) years posttransplantation and from 114 healthy control persons.

214 carriage (EPLs; 14-65 days of gestation) and healthy control placentae (various gestational ages) wer

215 study under tightly controlled conditions in healthy controls, pre-diabetic individuals and patients

216 ly higher CD4+CD151+ T-cell frequencies than healthy controls, raising the possibility that proinflam

217 Sequencing of 57 sCJD patients, and healthy controls reveals differential expression of hsa-

218 ients) consisting of Parkinson's disease and healthy control samples from three different sources.

219 Across 26 studies, compared with healthy controls, septic patients had significantly (p <

220 533 individuals with 22q11DS and 330 matched healthy control subjects (age range, 6-56 years; 49% fem

221 ashlight method (mean age 49.6 years) and 50 healthy control subjects (mean age 31.3 years) were exam

222 d deviation]) were compared with those in 10 healthy control subjects (mean age, 50.3 years +/- 17.2)

223 rest in recently abstinent CDSs (n = 24) and healthy control subjects (n = 36) both before and after

224 ither sex with varying degrees of psychosis: healthy control subjects (n = 46), schizophrenia patient

225 ural T(1)-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients wit

226 epithelial cells (PBECs) were isolated from healthy control subjects and patients with COPD and infe

227 s and subcortical volume differences between healthy control subjects and psychiatric patients from 1

228 bronchial brushings were also obtained from healthy control subjects comprising of adolescents admit

229 rs studied 66 schizophrenia patients and 143 healthy control subjects during performance of context u

230 h biallelic PRKN/PINK1 mutations compared to healthy control subjects in a German cohort, supporting

231 Patients with HFpEF and healthy control subjects of similar age and sex distribu

232 (mean deviation between 0 and - 6 dB) and 68 healthy control subjects selected by Propensity Score Ma

233 le sclerosis participants and 11 age-matched healthy control subjects to undergo 7 T imaging of the c

234 d-positive mild cognitive impairment) and 29 healthy control subjects underwent baseline assessment w

235 s, n = 14, and nonresponders, n = 15) and 26 healthy control subjects underwent detailed sensory prof

236 h schizophrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance sp

237 h current depressive symptoms and 10 matched healthy control subjects were analyzed as well.

238 eyes with PXS, 84 eyes with PXG, and 44 eyes healthy control subjects were analyzed.

239 supranuclear palsy-frontal subtypes) and 20 healthy control subjects were included.

240 Nonlesional skin of patients with AD and healthy control subjects were sampled at 2 time points s

241 CHR patients could be classified against healthy control subjects with 78% sensitivity and 77% sp

242 ts) before and 42 patients (compared with 52 healthy control subjects) after an exposure-based CBT.

243 ients with panic disorder (compared with 150 healthy control subjects) before and 42 patients (compar

244 on (b = .056, p = .035) in both patients and healthy control subjects, although the association with

245 was performed in 263 CHR individuals and 51 healthy control subjects, who were then clinically monit

246 ion carriers, and 82 demographically matched healthy control subjects.

247 ptomic differences compared neutrophils from healthy control subjects.

248 n the cortical regions in CDSs compared with healthy control subjects.

249 BD) exempt of Parkinsonian signs compared to healthy control subjects.

250 out chronic erythromycin administration, and healthy control subjects.

251 n patients with major depression relative to healthy control subjects.

252 ar composition in schizophrenia patients and healthy control subjects.

253 t in patients with IBD compared with that in healthy control subjects.

254 venous hydrocortisone challenge (CORT) in 19 healthy control subjects.

255 um cells from nine subjects with CF and five healthy control subjects.

256 ead and macula was conducted in patients and healthy control subjects.

257 gnosed SDB warranting adenotonsillectomy and healthy control subjects.Methods: Thirty children who ha

258 f FXTAS over time as compared to non-carrier healthy controls, suggesting a potential role in the dev

259 tion in patient-derived myotubes compared to healthy controls, suggesting a transcriptional mechanism

260 HBS1 are expressed at higher levels than the healthy controls, supporting a pathological role of this

261 In patients with Fabry disease, compared to healthy controls the mean average white matter fractiona

262 d between prodromal Huntington's disease and healthy controls, the noted associations suggest that di

263 utility for gout monitoring in patients and healthy controls through a purine-rich meal challenge.

264 8 pairs of tumour tissue samples and matched healthy control tissue from Chinese patients with primar

265 C9orf72 expansion adult carriers compared to healthy controls to characterize preclinical cerebral ch

266 skeletal muscle biopsies in CFS patients and healthy controls to look at cellular bioenergetic functi

267 forms and compared with age- and sex-matched healthy controls to provide insights into differential r

268 Crohn's disease epithelium alongside matched healthy controls to reveal disease-associated changes in

269 Sixteen healthy controls underwent a single challenge with dilue

270 d hemoglobin, 6.9+/-1.0%) and 12 age-matched healthy controls underwent assessment of cardiac systoli

271 98 participants with PD and 26 healthy controls underwent CCM with automated corneal ne

272 al female patients with lymphoma compared to healthy controls using electrochemiluminescence immunoas

273 e induced to express Abeta42 and age-matched healthy controls using label-free quantitative ion-mobil

274 ment in newborn infants with CHD compared to healthy controls using tensor-based morphometry (TBM).

275 uals (38 male) with mild AD or bvFTD, and in healthy controls, using a simultaneous resting-state fMR

276 K2 non-manifesting carriers (69 [36%] of 194 healthy controls vs 114 [55%] of 208 LRRK2 non-manifesti

277 sease Rating Scale (total score 4.6 [SD 4.4] healthy controls vs 8.4 [7.3] LRRK2 vs 9.5 [9.2] GBA, p<

278 : 0.885-1.009, p < 0.0001) and with CRC from healthy controls was 0.890 (95% CI: 0.809-0.972, p < 0.0

279 % CI: 0.925-1.020, p < 0.0001), with CD from healthy controls was 0.947 (95% CI: 0.885-1.009, p < 0.0

280 urve for separation of patients with UC from healthy controls was 0.972 (95% CI: 0.925-1.020, p < 0.0

281 nal connectivity differed most from those of healthy controls was less responsive to psychotherapy tr

282 cal RTT, 9 epilepsy control patients, and 11 healthy controls, we applied paired-pulse transcranial m

283 large group of adult TD patients compared to healthy controls, we assessed waiting motor impulsivity

284 duals with common brain disorders and 11,257 healthy controls, we observe differential volume alterat

285 telet counts <30 x 109/L and 18 aged-matched healthy controls, we used susceptibility-weighted magnet

286 y differences between depressed patients and healthy controls were also evaluated with concurrent TMS

287 crobiomes of insomnia patients compared with healthy controls were characterized by lower microbial r

288 A total of 195 diabetic patients and 100 healthy controls were enrolled in the study.

289 Ps who were clinically stable and 14 matched healthy controls were enrolled.

290 ients as well as both knees of 26 apparently healthy controls were evaluated with a 7.5-12 MHz linear

291 ue and fibroblasts from subjects with DS and healthy controls were examined for the various retromer

292 h amyloid-negative neurodegeneration, and 17 healthy controls were included in a data-driven scaled s

293 rats bearing orthotopic U87 glioblastoma and healthy controls were investigated.

294 A total of 335 children (excluding ten healthy controls) were enrolled in the seven studies and

295 major depressive disorder (MDD) patients, 65 healthy controls) were included to build a melancholic M

296 vides a very good discrimination of ALS from healthy controls which is comparable to that obtained us

297 eBL patients than in geographically matched healthy controls, which previously underrepresented the

298 nguished individuals with schizophrenia from healthy controls with an accuracy exceeding 80% (sensiti

299 amples from 75 patients with COVID-19 and 75 healthy controls, with good concordance in fluorescence

300 ces in expression in patients compared to in healthy controls, with some expression differences uniqu